BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine

<p>– ATTRibute-CM demonstrated a significant tr</p>
<p>The post <a href="https://forextv.com/top-news/bridgebio-pharma-announces-publication-of-positive-results-from-phase-3-attribute-cm-study-of-acoramidis-for-patients-with-transthyretin-amyloid-cardiomyopathy-attr-cm-in-the-new-england-journal-of/">BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>